NovoCure (NVCR) to Release Earnings on Thursday

NovoCure (NASDAQ:NVCR - Get Free Report) is anticipated to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $161.30 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

NovoCure Trading Up 2.0 %

NASDAQ:NVCR traded up $0.44 on Friday, hitting $22.09. 1,032,305 shares of the stock were exchanged, compared to its average volume of 690,196. The stock has a fifty day moving average of $26.65 and a 200-day moving average of $21.36. The stock has a market cap of $2.39 billion, a PE ratio of -15.78 and a beta of 0.62. NovoCure has a fifty-two week low of $11.70 and a fifty-two week high of $34.13. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27.

Analyst Ratings Changes

NVCR has been the subject of a number of research reports. Piper Sandler upped their price target on shares of NovoCure from $28.00 to $42.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th. Evercore ISI upgraded shares of NovoCure from an "in-line" rating to an "outperform" rating and upped their target price for the company from $18.00 to $30.00 in a research note on Monday, December 2nd. Wedbush reiterated a "neutral" rating and issued a $29.00 price objective on shares of NovoCure in a report on Monday, January 13th. Finally, HC Wainwright restated a "buy" rating and set a $38.00 target price on shares of NovoCure in a research note on Tuesday, January 14th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $32.67.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua.